Clinical trials: Right-heart Hemodynamics
Hypertension Pulmonary Secondary, Heart Failure, Right Sided
Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
Phase 2 study to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects
- Conditions
- Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
- Trial name
- HELP (NCT03541603)
- Testing
- Levosimendan
- Where
- 16 sites in United States
- Volunteers
- 44 people
- Sponsor
- Tenax Therapeutics, Inc.
Pulmonary Hypertension
Safety of SonoVue on Pulmonary Hemodynamics
This is an intra-subject crossover comparative safety study to evaluate the effect of intravenous (IV) bolus injection of SonoVue on pulmonary hemodynamics.
- Trial name
- NCT01306292
- Testing
- SonoVue
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Bracco Diagnostics, Inc
Heart Failure
Relationship Between LINQ™ Subcutaneous Impedance and Right-sided Hemodynamic Measurements
The purpose of the ReLINQuish study is to characterize the relationship between subcutaneous impedance and hemodynamic measurements in patients with heart failure.
- Trial name
- NCT03608826
- Testing
- Investigational LINQ™ HF RAMware
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure
Right Ventricular (RV) Pacing in Early Post-operative Continuous Flow Left Ventricular Assist Device (LVAD)
Continuous right ventricular (RV) pacing demonstrates harm in patients with normal left ventricular (LV) function as well as in patients with cardiomyopathy and clinical heart failure.
- Trial name
- NCT01446796
- Testing
- Implantable Cardioverter-Defibrillator (subject's pre-existing ICD)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Duke University
Portopulmonary Hypertension
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
This is an Open Label, Multicenter, pilot clinical trial to assess the efficacy and safety of an oral selective Endothelin Receptor Antagonist (ambrisentan) in patients with portopulmonary hypertension.
- Trial name
- Portopulm (NCT01224210)
- Testing
- Ambrisentan
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tufts Medical Center
Pulmonary Hypertension
Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).
The design of this study is to conduct a comprehensive safety evaluation of the pulmonary hemodynamic effects of Optison. The study is being conducted in subjects referred for cardiac catheterization for clinical reasons.
- Trial name
- NCT00878878
- Testing
- Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Dextrose
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- GE Healthcare
Hypoplastic Left Heart Syndrome, Hypoplastic Right-sided Heart Complex
Ambrisentan in Single Ventricle
Purpose: To evaluate the pharmacokinetics, bioavailability and hemodynamic efficacy of ambrisentan after Fontan surgical palliation of single ventricle heart defects.
- Trial name
- NCT02080637
- Testing
- Ambrisentan
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Kevin Hill
Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease
Right Ventricular Hemodynamics Using Cardiac MRI in Patients COPD and OSA
The coexistence of chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) in the same patient has been termed overlap syndrome, affecting 1% of the U.S.
- Conditions
- Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease, Overlap Syndrome
- Trial name
- NCT02244957
- Testing
- Bi-level positive airway pressure (BPAP), Nocturnal oxygen
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of California, San Diego
Heart Disease
Sildenafil in Single Ventricle Patients
Patients with single ventricle anatomy undergo staged surgical palliation. The result is an "in series" circulation with pulmonary blood flow and cardiac output directly related to pulmonary vascular resistance.
- Trial name
- NCT01169519
- Testing
- Sildenafil by injection
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Duke University